LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
Dados de momentum (gestores comparáveis):
amplitude de detentores +4.0% ·
fluxo de ações +0.6% ·
novas posições líquidas +3.8%
— fórmula
Acumulação ampla — aumento de ações entre um número maior de detentores
Todos os dados de participação: apenas gestores 13F rastreados, posições em ações ordinárias, período de referência Q4 2024
| Trimestre | Detentores | Δ | Ações | Valor reportado | Novo | Saídas |
|---|---|---|---|---|---|---|
| Q2 2026 | 193 | +4 | 671.92M | $804.91B | +6 | −1 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | — |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | — |
| Q2 2024 | 22 | — | 112.43M | $101.75B | — | — |
| # | Gestor | Ações | Δ ações | Valor | Seu peso | Detido | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passivo) | 34.31M | — | $26.49B | 1.0% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 20.86M | -0.3% | $16.11B | 1.9% | ▼ Trim | 3 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 20.86M | -0.3% | $16.11B | 1.9% | ▼ Trim | 3 | SEC ↗ |
| 4 | Capital World Investors ✦ | 19.55M | -4.0% | $15.09B | 2.3% | ▼ Trim | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passivo) | 17.38M | +1.7% | $13.39B | 1.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passivo) | 17.38M | +1.7% | $13.39B | 1.0% | ▲ Add | 3 | SEC ↗ |
| 7 | PRIMECAP Management ✦ | 16.76M | -5.3% | $12.94B | 10.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 9 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 10 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 11 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 12 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 13 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 14 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 15 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 16 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 17 | Norges Bank ✦ (passivo) | 10.89M | +3.9% | $8.41B | 1.1% | ▲ Add | 3 | SEC ↗ |
| 18 | Fisher Asset Management ✦ | 5.24M | +3.5% | $4.04B | 1.6% | ▲ Add | 3 | SEC ↗ |
| 19 | Tiger Global Management ✦ | 1.31M | +35.1% | $1.01B | 3.8% | ▲ Add | 3 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 1.24M | +204.1% | $957.87M | 1.1% | ▲ Add | 3 | SEC ↗ |
| 21 | D. E. Shaw & Co. ✦ | 1.24M | +204.1% | $957.87M | 1.1% | ▲ Add | 3 | SEC ↗ |
| 22 | Millennium Management ✦ | 801.07K | -19.1% | $618.42M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 23 | Lone Pine Capital ✦ | 782.86K | Novo | $604.37M | 4.5% | New | 1 | SEC ↗ |
| 24 | Adage Capital Partners ✦ | 732.55K | -11.7% | $565.53M | 1.0% | ▼ Trim | 3 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 30 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 31 | Citadel Advisors ✦ | 611.27K | +184.1% | $471.90M | 0.4% | ▲ Add | 3 | SEC ↗ |
| 32 | Citadel Advisors ✦ | 611.27K | +184.1% | $471.90M | 0.4% | ▲ Add | 3 | SEC ↗ |
| 33 | Marshall Wace ✦ | 388.68K | -57.3% | $300.06M | 0.4% | ▼ Trim | 3 | SEC ↗ |
| 34 | Marshall Wace ✦ | 388.68K | -57.3% | $300.06M | 0.4% | ▼ Trim | 3 | SEC ↗ |
| 35 | Marshall Wace ✦ | 388.68K | -57.3% | $300.06M | 0.4% | ▼ Trim | 3 | SEC ↗ |
| 36 | Marshall Wace ✦ | 388.68K | -57.3% | $300.06M | 0.4% | ▼ Trim | 3 | SEC ↗ |
| 37 | Two Sigma Investments ✦ | 322.69K | +61.6% | $249.12M | 0.6% | ▲ Add | 3 | SEC ↗ |
| 38 | Coatue Management ✦ | 213.98K | -13.7% | $165.20M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 39 | Coatue Management ✦ | 213.98K | -13.7% | $165.20M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 40 | Coatue Management ✦ | 213.98K | -13.7% | $165.20M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 41 | Coatue Management ✦ | 213.98K | -13.7% | $165.20M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 42 | Coatue Management ✦ | 213.98K | -13.7% | $165.20M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 43 | Bridgewater Associates ✦ | 84.36K | +15.1% | $65.12M | 0.3% | ▲ Add | 3 | SEC ↗ |
| 44 | Duquesne Family Office ✦ | 62.19K | Novo | $48.01M | 1.4% | New | 1 | SEC ↗ |
| 45 | Renaissance Technologies ✦ | 54.12K | -79.0% | $41.78M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 46 | Dodge & Cox ✦ | 44.80K | -0.7% | $34.58M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 47 | Soros Fund Management ✦ | 33.64K | Novo | $25.97M | 0.7% | New | 1 | SEC ↗ |
| 48 | GAMCO Investors ✦ | 33.54K | -3.6% | $25.90M | 0.3% | ▼ Trim | 3 | SEC ↗ |
| 49 | Arrowstreet Capital ✦ | 14.85K | -99.1% | $11.46M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 50 | Gotham Asset Management ✦ | 5.78K | -32.1% | $4.46M | 0.0% | ▼ Trim | 3 | SEC ↗ |
"Peso do gestor" = a participação da posição no valor total de ações 13F reportado pelo gestor — a medida de convicção. ✦ = gestor curado.
Novos compradores
| Lone Pine Capital | $604.37M | 4.5% |
| Duquesne Family Office | $48.01M | 1.4% |
| Soros Fund Management | $25.97M | 0.7% |
Encerrado
| Viking Global Investors | $134.70M | era 0.5% |
| Point72 Asset Management | $11.66M | era 0.0% |
Contexto de mercado completo: entre TODOS os filers 13F (dados estruturados da SEC, Q1 2026): 4,323 detentores, 762.84M ações, $674.93B reportado. Este é um período diferente e mais antigo do que os dados do universo rastreado acima, e os dois nunca são combinados.
O que os detentores rastreados deste título mais frequentemente também detêm — contagens de participação compartilhada, não relações fundamentais.
Compras no mercado aberto (P)
Nenhuma compra direta no mercado por insiders em nossa janela de cobertura.
Vendas no mercado aberto (S)
Officer · 6.50K ações · $7.64M
Officer · 2.00K ações · $2.37M
Officer · 5.00K ações · $5.95M
Prêmios, exercícios e retenção fiscal nunca são contabilizados como compras ou vendas aqui. Metodologia
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…
ForbesThe Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…
WSJThe U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of…
ReutersThe once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…
WSJ